Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis |
| |
| Authors: | Brian C. Healy PhD Maria Antonietta Mazzola MD Vanessa Beynon MD Felipe Von Glehn MD PhD Anu Paul PhD Camilo Diaz‐Cruz MD Taha Gholipour MD Bonnie I. Glanz MD Pia Kivisakk MD Tanuja Chitnis MD Howard L. Weiner MD James D. Berry MD Roopali Gandhi PhD |
| |
| Affiliation: | 1. Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA;2. Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA |
| |
| Abstract: | Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58 : 261–269, 2018 |
| |
| Keywords: | ALS biomarkers disease comparisons longitudinal analysis microRNA serum |
|
|
